Truist Securities upgraded Tandem Diabetes Care (NasdaqGM:TNDM) from Hold to Buy on March 19, 2026. The average one-year price target for the company is now $29.72 per share, signifying a potential upside of 20.61% from the last closing price of $24.64 per share.
The projected annual revenue for Tandem Diabetes Care is estimated at $1,133 million, reflecting an 11.65% increase, with projected annual non-GAAP EPS of $0.01. Institutional ownership decreased by 34.53% in the last quarter, with 328 funds reporting positions in TNDM, down from 501. The total shares owned by institutions fell by 17.16% to 76,456K shares.
